Next generation sequencing-based measurable residual disease detection predicts outcomes in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation

Sensitive, scalable and affordable measurable residual disease (MRD) assays are needed to guide treatment decisions in acute myeloid leukemia (AML), particularly around allogeneic hematopoietic stem cell transplantation (allo-SCT). Next-generation sequencing (NGS)-based MRD assays offer broad appli...

Полное описание

Библиографические подробности

Главные авторы:	Simon M. Krauß, Tara Holloway, Anne Weigert, Lara Bischof, Donata Backhaus, Dominic Brauer, Jule Ussmann, Georg-Nikolaus Franke, Vladan Vučinić, Uwe Platzbecker, Sebastian Schwind, Madlen Jentzsch, Klaus H. Metzeler
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Ferrata Storti Foundation 2026-05-01
Серии:	Haematologica
Online-ссылка:	https://haematologica.org/article/view/14203
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!